Group 1 - The core viewpoint is that while there is a recognition of a potential bubble in AI, it is not yet at its final stage, indicating there is still room for growth [1] - The healthcare industry is viewed positively, with recommendations to buy since Q4 of last year and a maintained "overweight" stance starting June 2024 [1] - Most Chinese pharmaceutical companies are reported to have strong overseas profits, and the sector has been undervalued for a long time, with China leading in international patent applications and increasing its share in all technologies [1] Group 2 - Despite market expectations for the Federal Reserve to lower interest rates to 2.9% by the end of 2026, a final rate of 3.25% is anticipated [1] - Given the weakness of the US dollar, it is suggested to include some non-dollar bonds in investment portfolios for diversification [1] - An "overweight" stance on emerging market bonds is recommended, as they are expected to benefit from current market conditions [1]
瑞士宝盛：AI有泡沫但仍存在上升空间 看好中国医疗板块
Zhi Tong Cai Jing·2026-01-08 11:31